{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:10:34Z","timestamp":1793171434588,"version":"4.5.0"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamainternmed.2021.6745","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T16:04:49Z","timestamp":1637597089000},"page":"33","source":"Crossref","is-referenced-by-count":120,"title":["Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis"],"prefix":"10.1001","volume":"182","author":[{"given":"William James","family":"Deardorff","sequence":"first","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, University of California, San Francisco"},{"name":"Geriatrics, Palliative and Extended Care Service Line, San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Cenzer","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, University of California, San Francisco"},{"name":"Geriatrics, Palliative and Extended Care Service Line, San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, University of California, San Francisco"},{"name":"Geriatrics, Palliative and Extended Care Service Line, San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, University of California, San Francisco"},{"name":"Geriatrics, Palliative and Extended Care Service Line, San Francisco Veterans Affairs Health Care System, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"ioi210068r1","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10192","article-title":"Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States.","volume":"3","author":"Lewiecki","year":"2019","journal-title":"JBMR Plus"},{"issue":"11","key":"ioi210068r2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/aje\/kwg081","article-title":"Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged.","volume":"157","author":"Magaziner","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"10","key":"ioi210068r3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s00198-004-1622-5","article-title":"Health-related quality of life after osteoporotic fractures.","volume":"15","author":"Hallberg","year":"2004","journal-title":"Osteoporos Int"},{"issue":"10","key":"ioi210068r4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review.","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"issue":"4","key":"ioi210068r5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1532-5415.2010.02769.x","article-title":"Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture.","volume":"58","author":"Jennings","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"ioi210068r6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.v29.9","article-title":"Osteoporosis medication use after hip fracture in US patients between 2002 and 2011.","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"ioi210068r7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamainternmed.2020.2975","article-title":"Incidence of hip fracture over 4 decades in the Framingham Heart Study.","volume":"180","author":"Swayambunathan","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"8","key":"ioi210068r8","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/jbmr.2832","article-title":"Impact of the US Food and Drug Administration\u2019s safety-related announcements on the use of bisphosphonates after hip fracture.","volume":"31","author":"Kim","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"3","key":"ioi210068r9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","article-title":"Hip fracture trends in the United States, 2002 to 2015.","volume":"29","author":"Lewiecki","year":"2018","journal-title":"Osteoporos Int"},{"issue":"5","key":"ioi210068r10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline.","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"ioi210068r11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management.","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"ioi210068r12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses.","volume":"13","author":"Olson","year":"2007","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"ioi210068r13","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid.","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"ioi210068r14","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1001\/jama.2013.282612","article-title":"Incorporating lag time to benefit into prevention decisions for older adults.","volume":"310","author":"Lee","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"ioi210068r15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women.","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporos Int"},{"issue":"10","key":"ioi210068r16","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/gerona\/glt092","article-title":"Epidemiology of fracture risk with advancing age.","volume":"68","author":"Ensrud","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ioi210068r17","article-title":"Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.","volume":"346","author":"Lee","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"ioi210068r18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis.","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"5","key":"ioi210068r19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40266-016-0344-7","article-title":"Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate.","volume":"33","author":"van de Glind","year":"2016","journal-title":"Drugs Aging"},{"issue":"1","key":"ioi210068r22","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"ioi210068r23","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"ioi210068r24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ioi210068r25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ioi210068r26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update.","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"11","key":"ioi210068r27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians.","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"ioi210068r28","doi-asserted-by":"publisher","first-page":"P1238","DOI":"10.4065\/80.9.1238","article-title":"Alendronate and vertebral fracture risk: in response.","volume":"80","author":"Quandt","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"ioi210068r30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.chb.2015.09.008","article-title":"Comparative evaluation of the reliability and validity of three data extraction programs: UnGraph, GraphClick, and DigitizeIt.","volume":"55","author":"Rakap","year":"2016","journal-title":"Comput Hum Behav"},{"issue":"4","key":"ioi210068r32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves.","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"issue":"22","key":"ioi210068r33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi210068r34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study.","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"issue":"9041","key":"ioi210068r35","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"ioi210068r36","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"14","key":"ioi210068r37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial.","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"ioi210068r38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"ioi210068r39","first-page":"111","article-title":"Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass.","volume":"8","author":"McClung","year":"1998","journal-title":"Osteoporosis Int"},{"issue":"5","key":"ioi210068r40","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial.","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"ioi210068r41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"18","key":"ioi210068r42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi210068r43","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial.","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ioi210068r44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","article-title":"Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.","volume":"74","author":"Harrington","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"ioi210068r45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1185\/030079903125003125","article-title":"Efficacy of risedronate on clinical vertebral fractures within six months.","volume":"20","author":"Roux","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"ioi210068r46","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/ard.56.9.510","article-title":"How do bisphosphonates prevent fractures?","volume":"56","author":"Tobias","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ioi210068r47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1359\/jbmr.081108","article-title":"Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength.","volume":"24","author":"Holzer","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"ioi210068r48","first-page":"488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation.","volume":"4","author":"Ettinger","year":"1998","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"ioi210068r49","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s12325-016-0360-3","article-title":"Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates.","volume":"33","author":"Goldshtein","year":"2016","journal-title":"Adv Ther"},{"key":"ioi210068r50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.573976","article-title":"Oral treatment with bisphosphonates of osteoporosis does not increase the risk of severe gastrointestinal side effects: a meta-analysis of randomized controlled trials.","volume":"11","author":"Domotor","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"ioi210068r51","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"ioi210068r52","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.clinthera.2015.03.018","article-title":"Gastrointestinal events among patients initiating osteoporosis therapy: a retrospective administrative claims database analysis.","volume":"37","author":"Modi","year":"2015","journal-title":"Clin Ther"},{"issue":"12","key":"ioi210068r53","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0149-2918(00)83042-8","article-title":"Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms.","volume":"22","author":"Miller","year":"2000","journal-title":"Clin Ther"},{"issue":"4","key":"ioi210068r54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial.","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"issue":"14","key":"ioi210068r55","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate.","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"ioi210068r56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos Int"},{"issue":"8","key":"ioi210068r57","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates.","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"ioi210068r58","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis.","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"issue":"8","key":"ioi210068r59","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/jamainternmed.2019.0682","article-title":"Association of disease definition, comorbidity burden, and prognosis with hip fracture probability among late-life women.","volume":"179","author":"Ensrud","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"8","key":"ioi210068r60","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamainternmed.2019.0688","article-title":"Considering the risks and benefits of osteoporosis treatment in older adults.","volume":"179","author":"Berry","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"11","key":"ioi210068r61","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/jgs.2004.52.issue-11","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.","volume":"52","author":"Boonen","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"ioi210068r62","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.","volume":"58","author":"Boonen","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"ioi210068r63","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/jgs.2019.67.issue-4","article-title":"Effect of bisphosphonates on fracture outcomes among frail older adults.","volume":"67","author":"Zullo","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"ioi210068r64","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1359\/JBMR.050104","article-title":"Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.","volume":"20","author":"Hochberg","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"10","key":"ioi210068r65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. a randomized, double-blind, placebo-controlled trial.","volume":"136","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"10","key":"ioi210068r66","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis.","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"ioi210068r29","year":"2015"},{"key":"ioi210068r20","unstructured":"Viswanathan? M, Reddy? S, Berkman? N, . Screening to Prevent Osteoporotic Fractures: An Evidence Review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality; 2018. Report No. 15-05226-EF-1. Accessed December 11, 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532075"},{"key":"ioi210068r21","unstructured":"Crandall? CJ, Newberry? SJ, Diamant? A, . Treatment to Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report. Agency for Healthcare Research and Quality; 2012. Report No. 12-EHC023-EF. Accessed December 11, 2020. https:\/\/pubmed.ncbi.nlm.nih.gov\/22553885"},{"key":"ioi210068r31","unstructured":"Wei? Y, Royston? P. IPDFC: Stata module to reconstruct individual participant data from a published Kaplan-Meier curve. Boston College Dept of Economics; 2020. Accessed March 8, 2021. https:\/\/ideas.repec.org\/c\/boc\/bocode\/s458867.html"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2786013\/jamainternal_deardorff_2021_oi_210068_1640813843.02769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:11:43Z","timestamp":1641312703000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2786013"}},"subtitle":["A Meta-analysis of Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2021.6745","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}